News Headlines

  1. Catalent Completes $5.5M Phased Clinical Storage Expansion At Kansas City Campus
    5/17/2018

    Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, recently announced it has completed the second phase of a $5.5M expansion program at its Kansas City, Missouri facility, to increase the controlled-substance and controlled-temperature storage capabilities for its clinical supply business.

  2. Greenphire Shares Key Findings Of Site Payment Advisory Group
    5/17/2018

    Greenphire, the global leader in financial software for clinical trials, recently released key findings from meetings with nearly a dozen Clinical Research Organizations (CROs) from its Site Payment Advisory Group on the topic of investigator payment processes.

  3. Sanofi: Dupixent (dupilumab) Showed Positive Phase 3 Results In Adolescents With Inadequately Controlled Moderate-To-Severe Atopic Dermatitis
    5/16/2018

    A pivotal Phase 3 trial evaluating Dupixent (dupilumab) to treat moderate-to-severe atopic dermatitis in adolescents (ages 12-17) met its primary and key secondary endpoints.

  4. Albireo Enrolls First Patient In Phase 3 PFIC Trial Of A4250
    5/16/2018

    Albireo Pharma, Inc. (Nasdaq:ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced the first patient has been enrolled in PEDFIC-1, a Phase 3 clinical trial of lead product candidate A4250, an ileal bile acid transporter (IBAT) inhibitor being studied for the treatment of patients with progressive familial intrahepatic cholestasis (PFIC).

  5. LMC Manna Research Acquires Omnispec Clinical Research
    5/15/2018

    LMC Manna Research – the largest network of fully-owned and integrated clinical research sites in Canada providing Phase I-IV clinical trial services – recently announced the acquisition of leading Montreal-based research centre Omnispec Clinical Research.

  6. New Real-Time Architecture And UI Innovations In Veeva CRM Deliver Information To Any Device For Greater Field Productivity
    5/15/2018

    Veeva Commercial & Medical Summit - Veeva Systems recently announced mobile innovations in Veeva CRM that empower field teams with the information they need from any device.

  7. Veeva Introduces Next-Generation Commercial Data Warehouse For Life Sciences
    5/15/2018

    Veeva Commercial & Medical Summit - Veeva Systems recently introduced a new commercial data warehouse for life sciences. Veeva Nitro eliminates the burden of custom-built data warehouses with an industry-specific data model and standard integrations that unify companies’ most important data sources.

  8. Lilly's Galcanezumab Meets Primary Endpoint In Phase 3 Study Evaluating Galcanezumab For The Prevention Of Episodic Cluster Headache
    5/15/2018

    Eli Lilly and Company (NYSE:LLY) announced today that galcanezumab met its primary endpoint in a Phase 3 study of patients with episodic cluster headache, demonstrating statistically significant differences in the reduction of weekly cluster headache attacks compared to placebo across weeks one to three of the two-month, double-blind treatment period.

  9. Oryzon Announces First Patients In ETHERAL: A Phase IIa Clinical Trial In Alzheimer’s Disease With ORY-2001
    5/14/2018

    Oryzon Genomics (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, has announced today the inclusion last week of the First Patients in its Phase IIa clinical trial with ORY-2001 in mild and moderate Alzheimer’s disease patients.

  10. Soleno Therapeutics Announces Initiation Of Phase III Clinical Trial Of DCCR In Prader-Willi Syndrome
    5/14/2018

    Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it has initiated its multi-center Phase III clinical trial of Diazoxide Choline Controlled-Release (“DCCR”) for the treatment of Prader-Willi Syndrome (“PWS”). Seattle Children’s Hospital is the first site to be activated and Parisa Salehi, M.D., is the Principal Investigator for the trial at this site.